Patents Examined by Jeanine A. Goldberg
  • Patent number: 10774381
    Abstract: The present invention relates to a genetic marker for determining meat quality traits of pigs and a use thereof, and specifically, a genetic marker for determining meat quality traits of pigs, comprising a polynucleotide consisting of 5 to 300 consecutive nucleotides comprising the nucleotides from the 1524th to the 1527th positions in the polynucleotide of SEQ ID NO: 1, or a polynucleotide complementary thereto, a composition for determining meat quality traits of pigs comprising an agent capable of detecting the genetic marker, a composition for determining Korean native pigs, a kit, a microarray, a method for determining meat quality traits of pigs, and a method for determining meat quality traits of Korean native pigs.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 15, 2020
    Assignees: REPUBLIC OF KOREA (MANAGEMENT: RURAL DEVELOPMENT ADMINISTRATION), KOREA RESEARCH INSTITUTE OF BIOSCIENCES AND BIOTECHNOLOGY, JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: In Cheol Cho, Hee Bok Park, Jeong Woong Lee, Jin Seop Ahn, Sang Hyun Han
  • Patent number: 10770183
    Abstract: The present invention provides method of classifying a subject into a necrotizing meningoencephalitis (NME) disease risk group. The method may include assessing the presence of one or more marker (e.g., SNPs or risk loci) in a sample from the subject. For example, detection of the presence of one or more markers that are associated with an increased risk of NME can indicate that the subject should be classified into a risk group.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: September 8, 2020
    Assignees: The Translational Genomics Research Institute, University of Georgia Research Foundation, Inc.
    Inventors: Matthew Huentelman, Scott Schatzberg, Renee Barber
  • Patent number: 10760137
    Abstract: Methods for the rapid detection of the presence or absence of Babesia in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting Babesia and kits are provided that are designed for the detection of Babesia, including, but not limited to, the Babesia species of B. microti, B. divergens, B. duncani, and B. venatorum. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of Babesia.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: September 1, 2020
    Inventors: Ellen H. Fiss, Jingtao Sun
  • Patent number: 10745732
    Abstract: The present disclosure relates to genetic markers for discrimination and detection of bacteria causing Edwardsiellosis and Streptococcosis in fish, and a method for discriminating and detecting the bacteria using the same. A genetic marker for discrimination and/or detection of each of Edwardsiella tarda, Streptococcus iniae, Streptococcus parauberis and Lactococcus garvieae, which cause fish diseases, is selected and a peptide nucleic acid and a primer pair, which are specific for the genetic marker, are used to amplify and obtain melting curves having different fluorescences depending on bacterial species. Thus, bacteria that cause fish diseases can be discriminated and whether or not fish would be infected with the bacteria can be detected in a simple, rapid and accurate manner.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 18, 2020
    Assignee: NATIONAL INSTITUTE OF FISHERIES SCIENCE
    Inventors: Myoung Sug Kim, Sung-Hee Jung, Hye Sung Choi, Hyun-Ja Han, Jeung-Wan Do, Jin-Do Kim
  • Patent number: 10731219
    Abstract: The method for preventing progression to metabolic syndrome includes determining whether a subject possesses at least one allele of the caveolin-1 rs1997623 C to A SNP, and providing an intervention to prevent progression to metabolic syndrome, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with MetS, such as heart disease, stroke, or diabetes. The method may include monitoring additional metabolic risk factors. The pharmaceutical compound may be a pharmaceutical capable of inhibiting the expression of caveolin-1.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 4, 2020
    Assignee: Dasman Diabetes Institute
    Inventors: Fahd Al Mulla, Rasheeba Nizam, Ashraf Madhoun
  • Patent number: 10731217
    Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: August 4, 2020
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Nancy Bo Yin Tsui
  • Patent number: 10724098
    Abstract: Methods and kits for diagnosing propensity to exhibit acquired peripheral neuropathy in dogs are described. The methods and kits test dogs for presence of a single-nucleotide polymorphism (SNP) TIGRP2P18586_rs8746233. Presence of the SNP indicates an increased likelihood of the dog exhibiting an acquired peripheral neuropathy. This information can be used to guide preemptive clinical treatment of the animal for peripheral neuropathy and to choose dogs for selective breeding programs.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 28, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peter Muir, Susannah Sample, John Svaren
  • Patent number: 10724093
    Abstract: This invention intends to develop many DNA markers for a plant of the genus Fragaria and detect powdery mildew resistance with high precision by using the many DNA markers. The marker associated with powdery mildew resistance in a plant of the genus Fragaria comprises a continuous nucleic acid region sandwiched between the nucleotide sequence as shown in SEQ ID NO: 1 and the nucleotide sequence as shown in SEQ ID NO: 19 in the chromosome of the plant of the genus Fragaria.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 28, 2020
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Hiroaki Koishihara, Hiroyuki Enoki, Masayoshi Muramatsu, Satoru Nishimura, Susumu Yui, Masanori Honjo
  • Patent number: 10718023
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 21, 2020
    Assignee: Celera Corporation
    Inventor: Hongjin Huang
  • Patent number: 10711305
    Abstract: The present invention relates to a method for the detection of the presence or absence of at least one nucleic acid sequence specific for the sex of chicken using polymerase chain reaction in a high-throughput manner, a kit for conducting the method of the present invention and a pair of oligonucleotides.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 14, 2020
    Assignee: DIREGG GMBH
    Inventors: Martin Christian Weigel, Karsten Hofmann-Peiker, Michael Kleine
  • Patent number: 10704103
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of, e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: July 7, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Samer Waleed Khedheyer Al-Murrani, Xiangming Gao
  • Patent number: 10704102
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of, e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: July 7, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Samer Waleed Khedheyer Al-Murrani, Xiangming Gao
  • Patent number: 10697021
    Abstract: The present invention provides a method of diagnosing a breast cancer central nervous system (CNS) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain or breast cells; and correlating an increase or decrease of the subject-derived expression level as compared to the normal control level to a diagnosis of a breast cancer CNS metastasis. The present invention also provides a method for the treatment of a breast cancer CNS metastasis in a subject comprising administering to the subject an inhibitor of an overexpressed gene associated with CNS metastasis.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 30, 2020
    Assignee: The Translational Genomics Research Institute
    Inventor: Bodour Salhia
  • Patent number: 10689711
    Abstract: This invention relates to methods for detecting the presence of genetic markers for transitional cell carcinoma of the bladder. Specifically, this invention relates to detection of expression of overexpressed and underexpressed genetic markers and calculation of ratios of expression of these markers. In additional aspects, the invention relates to polymerase chain reaction (PCR) based kits for carrying out these methods.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: June 23, 2020
    Assignee: PACIFIC EDGE LIMITED
    Inventor: Parry John Guilford
  • Patent number: 10683555
    Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Exact Sciences Development Company, LLC
    Inventors: David A. Ahlquist, John B. Kisiel, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi
  • Patent number: 10669590
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Blueprint Medicines Corporation
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • Patent number: 10662476
    Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 26, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
  • Patent number: 10662485
    Abstract: The present invention compositions, methods and systems to identify, detect, and/or quantify bacterial DNA in the presence of contaminating non-bacterial DNA. In particular, the present invention provides oligonucleotides configured to detect a relatively small amount of bacterial DNA in the presence of an overwhelmingly large amount of contaminating human DNA.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: May 26, 2020
    Assignee: IBIS BIOSCIENCES, INC.
    Inventors: David J. Ecker, Steven A. Hofstadler, Rangarajan Sampath, Lawrence B. Blyn, Thomas A. Hall, Mark W. Eshoo
  • Patent number: 10655187
    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 19, 2020
    Assignee: GENCURIX INC.
    Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho
  • Patent number: 10626473
    Abstract: Provided herein is a highly sensitive and robust method for Zika detection in semen, as well as related compositions. The method can include: (a) extracting nucleic acids from a human semen sample; (b) detecting Zika virus nonstructural protein 5 (NS5) mRNA using real-time reverse-transcription polymerase chain reaction (rRT-PCR); and (c) simultaneously, in the rRT-PCR, detecting human beta-actin mRNA as positive control.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Genetics & IVG Institute, Inc.
    Inventors: Brian D. Mariani, Harvey J. Stern